Schott Pharma FY26 Q3 EBITDA margin drops 2.1 percentage points to 26.8%; revenue rises 10% to EUR 281.8 million

Reuters2026/08/12 05:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Schott Pharma reported Q3 revenue up 10% to EUR 281.8 million, lifting 9M revenue 4.1% to EUR 769.8 million.
9M EBITDA fell to EUR 205.3 million, pushing the EBITDA margin down 2.2 percentage points to 26.7%.
Free cash flow improved 49% to EUR 58.9 million in 9M, while 9M capex edged down to EUR 82.5 million.
DCS revenue rose 7.6% to EUR 445.4 million in 9M; DDS revenue slipped 0.2% to EUR 325.1 million.
Management flagged stronger demand for polymer syringes outside mRNA, confirmed FY2026 revenue growth of 5%-6% and EBITDA margin of 27%-28%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schott Pharma AG & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2380588_de) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Schott Pharma FY26 Q3 EBITDA margin drops 2.1 percentage points to 26.8%; revenue rises 10% to EUR 281.8 million

You may also like

Crypto prices